Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HRH1 | P35367 | 3/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619282 | 1.00 | LMNA (0.52) | LMNAMIFTAAR1HTR2AHRH1 | |
| SCHEMBL2588402 | 1.00 | LMNA (0.52) | LMNAMIFTAAR1HTR2AHRH1 | |
| SCHEMBL3248164 | 0.80 | AOC3 (0.46) | LMNATAAR1HTR2AHRH1AOC3 | |
| SCHEMBL11268892 | 0.77 | ADRB2 (0.46) | LMNAAOC3TDP1 | |
| SCHEMBL41745 | 0.77 | POLB (0.45) | LMNAHTR2AHRH1AOC3POLB | |
| SCHEMBL54346 | 0.75 | HTR2A (0.59) | LMNAMIFTAAR1HTR2AHRH1 | |
| SCHEMBL3898638 | 0.74 | LMNA (0.52) | LMNAMIFTAAR1HTR2AHRH1 | |
| SCHEMBL7707874 | 0.74 | TRPA1 (0.45) | LMNATAAR1HTR2ATRPA1 | |
| SCHEMBL17816146 | 0.74 | LMNA (0.52) | LMNAMIFTAAR1HTR2AHRH1 | |
| SCHEMBL2911715 | 0.74 | TRPA1 (0.45) | LMNATAAR1HTR2ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4268510-A | DEMETHANIZATION, METABOLISM, RUMEN | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-05-19 | — | — | US | claimed |
| EP-0010348-A1 | Heterocyclic trichloromethyl derivatives, process for their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-04-30 | — | — | EP | claimed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9412487-B2 | Silver-(conjugated compound) composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20140001422-A1 | COMPOSITION OF SILVER-CONJUGATED COMPOUND COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-2497475-A1 | Treatment of laminitis with platelet aggregation inhibitors | Dussler, Sabine (DE) | 2012-09-12 | — | — | EP | disclosed |
| EP-2478981-A1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | Sumitomo Chemical Co., Ltd (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120168693-A1 | SILVER-(CONJUGATED COMPOUND) COMPOSITE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-20110226622-A1 | NOVEL CLEAR NATIVE ELECTROPHORESIS METHOD UTILIZING AROMATIC SULFONIC ACID COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2357469-A1 | NOVEL CLEAR NATIVE ELECTROPHORESIS METHOD UTILIZING AROMATIC SULFONIC ACID COMPOUND | Japan Science and Technology Agency (JP) | 2011-08-17 | — | — | EP | disclosed |
| US-5288726-A | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | UBE INDUSTRIES LIMITED (JP) | 1994-02-22 | — | — | US | disclosed |
| EP-0542411-A2 | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | Sankyo Company Limited (JP) | 1993-05-19 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4728646-A | ANTITHROMBOTICS | DR. KARL THOMAE GMBH (DE) | 1988-03-01 | — | — | US | disclosed |
| US-4690923-A | ANTITHROMBOTICS | KARL THOMAE GMBH (DE) | 1987-09-01 | — | — | US | disclosed |
| US-4518596-A | Antithrombotic use of 2-(perhydro-1,4-diazino)-pyrimido (5,4,D)-pyrimidines | DR. KARL THOMAE GMBH (DE) | 1985-05-21 | — | — | US | disclosed |
| EP-0023559-B1 | 2-(PERHYDRO-1,4-DIAZINO)-PYRIMIDO(5,4-D)PYRIMIDINES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4362738-A | ANTIINFLAMMATORIES | DR. KARL THOMAE GMBH (DE) | 1982-12-07 | — | — | US | disclosed |
| EP-0023559-A1 | 2-(Perhydro-1,4-diazino)-pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110226622-A1 | NOVEL CLEAR NATIVE ELECTROPHORESIS METHOD UTILIZING AROMATIC SULFONIC ACID COMPOUND | IK, CHAMP1, RAB5IF | LMNA 1378/4885MIF 4467/4885TAAR1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.